Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04050436 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04050436 · ClinicalTrials.gov record · last posted 2025-01-27

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Study acronym: CERPASS
StatusActive, Not Recruiting
PhasePhase 2
Started2019-10-08
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 27, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.

Amendment record 24 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 24 times since 2019-08-07; most recent amendment 2025-01-22. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-02-01
Status change Recruiting→Active, Not Recruitingv22
2019-09-09
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT04050436
Lead Sponsor Replimune, Inc.
Collaborators: Regeneron Pharmaceuticals
Conditions Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
Enrollment 231 participants
Start Date 2019-10-08
Primary Completion 2025-09 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2025-01-27